Literature DB >> 9636541

Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation.

B Charpentier1, E Thervet.   

Abstract

Mesh:

Substances:

Year:  1998        PMID: 9636541     DOI: 10.1016/s0041-1345(98)00264-4

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  4 in total

Review 1.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

2.  Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.

Authors:  Tainá Veras de Sandes-Freitas; Cláudia Rosso Felipe; Marcello Fabiano de Franco; Hélio Tedesco-Silva; José Osmar Medina-Pestana
Journal:  Int Urol Nephrol       Date:  2012-10-11       Impact factor: 2.370

Review 3.  Interleukin 2 receptor antagonists for kidney transplant recipients.

Authors:  Angela C Webster; Lorenn P Ruster; Richard McGee; Sandra L Matheson; Gail Y Higgins; Narelle S Willis; Jeremy R Chapman; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

4.  Implication of interleukin-2 receptor antibody induction therapy in standard risk renal transplant in the tacrolimus era: a meta-analysis.

Authors:  Hatem Ali; Atif Mohiuddin; Ajay Sharma; Ihab Shaheen; Jon Jin Kim; Mohsen El Kosi; Ahmed Halawa
Journal:  Clin Kidney J       Date:  2019-01-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.